Quantitative Clinical Pharmacology, AstraZeneca LP, Waltham, Massachusetts, USA.
Clin Pharmacol Ther. 2017 Nov;102(5):741-744. doi: 10.1002/cpt.719. Epub 2017 May 26.
Naloxegol is a peripherally acting μ-opioid receptor antagonist that was developed for the treatment of opioid-induced constipation. Modeling and simulation of naloxegol efficacy and tolerability informed selection of doses for phase III studies and provided comprehensive dosage recommendations for the naloxegol US package insert.
纳洛酮是一种外周作用的 μ 阿片受体拮抗剂,用于治疗阿片类药物引起的便秘。纳洛酮疗效和耐受性的建模和模拟为 III 期研究选择剂量提供了信息,并为纳洛酮美国说明书提供了全面的剂量建议。